利伐沙班或依诺肝素在下肢非大骨科手术中的比较
这项国际、平行组、随机、双盲、非劣效性试验纳入3604例因下肢非大骨科手术而制动、研究者判断存在静脉血栓栓塞风险的成人患者,随机接受利伐沙班(1809例)或依诺肝素(1795例)。主要疗效终点为主要静脉血栓栓塞(症状性远端或近端深静脉血栓、肺栓塞或血栓栓塞相关死亡,或治疗结束时无症状近端深静脉血栓)的复合终点。利伐沙班组4/1661例(0.2%)发生主要静脉血栓栓塞,依诺肝素组18/1640例(1.1%)(多重插补风险比0.25,95%CI 0.09-0.75;非劣效性P<0.001;优效性P=0.01)。两组出血发生率无显著差异(大出血或临床相关非大出血分别为1.1%和1.0%;大出血分别为0.6%和0.7%)。结论认为利伐沙班在预防静脉血栓栓塞事件方面比依诺肝素更有效。
要点
- 下肢非大骨科手术后制动期,利伐沙班较依诺肝素显著降低主要静脉血栓栓塞:0.2%(4/1661)vs 1.1%(18/1640),RR 0.25(95%CI 0.09-0.75),优效性P=0.01。
- 利伐沙班非劣效于依诺肝素(非劣效性P<0.001),并达到优效。
- 大出血或临床相关非大出血发生率利伐沙班组1.1% vs 依诺肝素组1.0%,无显著差异。
- 大出血发生率利伐沙班组0.6% vs 依诺肝素组0.7%,无显著差异。
- 研究纳入标准为研究者判断存在静脉血栓栓塞风险的下肢非大骨科手术成人患者。
适用人群与场景
- 接受下肢非大骨科手术、因制动而存在静脉血栓栓塞风险的成人患者,风险由研究者判断。
研究设计与关键结果
- 研究类型:国际、平行组、随机、双盲、非劣效性试验;样本量3604例(利伐沙班组1809例,依诺肝素组1795例)。
- 主要疗效终点为主要静脉血栓栓塞复合终点(症状性远端或近端深静脉血栓、肺栓塞或静脉血栓栓塞相关死亡,或治疗结束时无症状近端深静脉血栓)。
- 主要终点结果:利伐沙班组4/1661例(0.2%)vs 依诺肝素组18/1640例(1.1%),多重插补风险比0.25(95%CI 0.09-0.75),非劣效性P<0.001,优效性P=0.01。
- 安全性终点:大出血或临床相关非大出血利伐沙班组1.1% vs 依诺肝素组1.0%,无显著差异;大出血利伐沙班组0.6% vs 依诺肝素组0.7%,无显著差异。
- 研究期间对缺失数据采用多重插补;若利伐沙班非劣效则计划进行优效性检验。
证据类型、等级与局限
- 证据类型:国际、随机、双盲、非劣效性试验(PRONOMOS,NCT02401594)。
- 资助方:圣艾蒂安大学医院中心和拜耳。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于下肢非大骨科手术后制动、研究者判断存在静脉血栓栓塞风险的成人患者,利伐沙班在预防主要静脉血栓栓塞方面比依诺肝素更有效,且出血发生率无显著差异。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Nonmajor orthopedic surgery of the lower limbs that results in transient reduced mobility places patients at risk for venous thromboembolism. Rivaroxaban may be noninferior to enoxaparin with regard to the prevention of major venous thromboembolism in these patients.
METHODS: In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin. The primary efficacy outcome of major venous thromboembolism was a composite of symptomatic distal or proximal deep-vein thrombosis, pulmonary embolism, or venous thromboembolism-related death during the treatment period or asymptomatic proximal deep-vein thrombosis at the end of treatment. A test for superiority was planned if rivaroxaban proved to be noninferior to enoxaparin. For all outcomes, multiple imputation was used to account for missing data. Prespecified safety outcomes included major bleeding (fatal, critical, or clinically overt bleeding or bleeding at the surgical site leading to intervention) and nonmajor clinically relevant bleeding.
RESULTS: A total of 3604 patients underwent randomization; 1809 patients were assigned to receive rivaroxaban, and 1795 to receive enoxaparin. Major venous thromboembolism occurred in 4 of 1661 patients (0.2%) in the rivaroxaban group and in 18 of 1640 patients (1.1%) in the enoxaparin group (risk ratio with multiple imputation, 0.25; 95% confidence interval, 0.09 to 0.75; P<0.001 for noninferiority; P = 0.01 for superiority). The incidence of bleeding did not differ significantly between the rivaroxaban group and the enoxaparin group (1.1% and 1.0%, respectively, for major bleeding or nonmajor clinically relevant bleeding; 0.6% and 0.7%, respectively, for major bleeding).
CONCLUSIONS: Rivaroxaban was more effective than enoxaparin in the prevention of venous thromboembolic events during a period of immobilization after nonmajor orthopedic surgery of the lower limbs. (Funded by Centre Hospitalier Universitaire de Saint-Etienne and Bayer; PRONOMOS ClinicalTrials.gov number, NCT02401594.).
参考来源
- Samama CM, Laporte S, Rosencher N, et al. Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. N Engl J Med. 2020. PMID: 32223113. doi:10.1056/NEJMoa1913808
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。